



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

Date: November 10, 2025

To,  
**Listing Compliance Department**  
**Bombay Stock Exchange Limited**  
**Phiroze Jeejeebhoy Tower, 25<sup>th</sup> Floor**  
**Dalal Street,**  
**Mumbai – 400 001**

**Scrip Code: 524727**

**Subject: Revised Outcome of the Board Meeting – November 10, 2025 after oversight correction**

Respected Sir,

We are pleased to inform you that:

1. At the Meeting of Board of Directors held on November 10, 2025, the Board of Director has approved the Unaudited Financial Results (Both Standalone & Consolidated) of the Company for the Quarter and Half Year Ended September 30, 2025.
2. At the meeting of the Board of Directors held on November 10, 2025, based on the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of Mr. Dharmesh Vinodbhai Desai (DIN: 00292502) as an Additional Non-Executive Independent Director on the Board of the Company with immediate effect for a period of five years commencing from November 10, 2025 to November 09, 2030, subject to the approval of the shareholders of the Company. The requisite details of proposed appointment pursuant to the requirement of Regulation 30 and other relevant provisions of the Listing Regulations are given as an Annexure I.
3. We wish to inform you that Mr. Nirav Dineshchandra Jogani (DIN: 00016354) vide letter dated November 10, 2025, has tendered his resignation as an Independent Director of the Company, with effect from close of business hours on November 10, 2025. While taking note of the above, the Board of Directors of the Company placed on record its appreciation for the valuable contribution and guidance provided by him during his association with the Company as an Independent Director. Please find enclosed relevant details required under Regulation 30 read with Schedule III –Para A(7B) of Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular dated November 11, 2024 in this regard, are given in Annexure – II. Mr. Nirav Dineshchandra Jogani has confirmed that there is no other material reason for his resignation other than as mentioned in his resignation letter. Copy of resignation letter received from him is enclosed herewith.

CIN: L74999GJ1980PLC003710

[www.span.in](http://www.span.in)



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: [contact@span.in](mailto:contact@span.in)

4. We wish to inform you that Dr. Pradipkumar Keshavlal Desai (DIN: 00026451) vide letter dated November 10, 2025, has tendered his resignation as Non-Executive and Non-Independent Director of the Company, with effect from close of business hours on November 10, 2025. While taking note of the above, the Board of Directors of the Company placed on record his huge contribution made by Dr. Pradipkumar Keshavlal Desai since foundation of Company and appreciation for the valuable contribution and guidance provided by him during his association with the Company as a Director. Please find enclosed relevant details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 in this regard, are given in Annexure – III. Dr. Pradipkumar Keshavlal Desai has confirmed that there is no other material reason for his resignation other than as mentioned in his resignation letter. Copy of resignation letter received from him is enclosed herewith.
5. The Board had on recommendation of the Nomination and Remuneration Committee (“NRC”) had in its meeting held on November 10, 2025, accepted his resignation and relinquish his position, as the Non – Executive - Non-Independent Director of the Company with effect from end of working hours of November 10, 2025. Further, considering his past service and a pivotal role played by him in establishing Company’s strong foundation, driving sustained growth, and fostering a culture of excellence, integrity, and innovation, and in recognition of his visionary leadership, dedication, and outstanding contributions to the Company’s progress, the Board of Directors had in consultation with and approval of the NRC, has requested and recommended Dr. Pradipkumar Keshavlal Desai to continue in providing his guidance and mentorship to the Company and be conferred with the honorary title of “Chairman Emeritus” w.e.f. November 10, 2025 post his resignation. In the capacity of Chairman Emeritus he is continuing in a Professional technical advisory role, offering guidance.



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

6. At the meeting of Board of Directors, Board approved the reconstitution of various Committees of the Board of Directors of the Company as under with immediate effect.

#### **RECONSTITUTION OF AUDIT COMMITTEE OF THE COMPANY**

<b>Sr. No.</b>	<b>Name of the Committee Member</b>	<b>Position</b>	<b>Category</b>
1	Mr. Rajendra Chokhawala	Chairman	Non-Executive Independent Director
2	Mr. Dharmesh Vinodbhai Desai	Member	Non-Executive Independent Director
3	Mr. Jignesh Desai	Member	Non-Executive Independent Director
4	Mr. Sanjay Mehta	Member	Non-Executive Non-Independent Director

#### **RECONSTITUTION OF STAKEHOLDERS RELATIONSHIP COMMITTEE OF THE COMPANY\***

<b>Sr. No.</b>	<b>Name of the Committee Member</b>	<b>Position</b>	<b>Category</b>
1	Mr. Sanjay Mehta	Chairman	Non-Executive Non-Independent Director
2	Mr. Dharmesh Vinodbhai Desai	Member	Non-Executive Independent Director
3	Mr. Rajendra Chokhawala	Member	Non-Executive Independent Director
4	Dr. Shefali Desai	Member	Non-Executive Non-Independent Director

\*An inadvertent oversight has been rectified.



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

## RECONSTITUTION OF NOMINATION AND REMUNERATION COMMITTEE OF THE COMPANY

Sr. No.	Name of the Committee Member	Position	Category
1	Mr. Dharmesh Vinodbhai Desai	Chairman	Non-Executive Independent Director
2	Mr. Rajendra Chokhawala	Member	Non-Executive Independent Director
3	Mr. Sanjay Mehta	Member	Non-Executive Non-Independent Director

7. In pursuant of shareholders' approval dated September 26, 2024, we wish to inform that Board at its meeting held on November 10, 2025, approved to sell / transfer or otherwise dispose-off the entire investments i.e. contribution of INR 99,000 aggregating to 99% stake held in Span Diagnostics LLP., a infructuous subsidiary LLP to the purchasers i.e. Mr. Viral P Desai and Ms. Sujata V Desai at a consideration of INR 99,000. The said subsidiary LLP is inoperative since its inception. The requisite details pursuant to the requirement of Regulation 30 and other relevant provisions of the Listing Regulations are given as an Annexure IV.
8. We wish to inform you that the Board of Directors of the Company at its meeting held today, i.e., November 10, 2025, inter alia, considered and approved proposal regarding exploration of various fund-raising avenues to strengthen the financial position of the Company and support its future growth initiatives. Based on the recommendation of the management, the Board approved the proposal to explore fund-raising options, including but not limited to a Fresh Public Offer (FPO), Preferential Allotment, or any other appropriate mode, as may be considered viable and in the best interests of the Company. The Board has authorised the management to undertake a detailed evaluation of various alternatives, market conditions, legal and regulatory implications, and to engage professional advisors, merchant bankers, and other intermediaries to assist in the process.

It was further noted that no definitive decision has been taken at this stage regarding the structure, size, or timing of any proposed fund-raising, which shall be placed before the Board for its consideration and approval in due course.

CIN: L74999GJ1980PLC003710

[www.span.in](http://www.span.in)



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: [contact@span.in](mailto:contact@span.in)

9. We wish to inform you that, in light of new business opportunities emerging, the assets of the Company's subsidiary LLP, namely M/s. Aranya Agri Biotech LLP, have been reclassified as part of Property, Plant and Equipment (PPE). After due deliberations, the Board has approved the plan to resume the operations of M/s. Aranya Agri Biotech LLP.

Board Meeting Commenced at 11:00 a.m. and concluded at 06:30 p.m.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

**For Span Divergent Limited**

**Viral Desai**  
**Managing Director**  
**DIN 00029219**



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

## ANNEXURE – I

Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

### Appointment of Mr. Dharmesh Vinodbhai Desai (DIN: 00292502) as an Additional Non-Executive Independent Director of the Company

Sr No.	Particulars	Details
1	Name	Mr. Dharmesh Vinodbhai Desai (DIN: 00292502)
2	Date of Birth	March 26, 1973
3	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	The Board of Directors on recommendation of the Nomination & Remuneration Committee proposed to appoint Mr. Dharmesh Vinodbhai Desai (DIN: 00292502) as an Additional Non – Executive, Independent Director of the Company with immediate effective from November 10, 2025 for a period of five years commencing from November 10, 2025 to November 09, 2030 subject to approval of shareholders of the Company.
4	Date of appointment & Terms of appointment	Appointment with effective from November 10, 2025 subject to approval shareholders of the Company as an Independent Director of the Company for the period of 5 years.
5	Brief Profile	Mr. Dharmesh V. Desai, is the Promoter and Chairman & Managing Director of Meera Industries Limited. He has completed his Bachelor of Engineering (Mechanical) from NIT Surat, South Gujarat University. He has experience of more than 20 (Twenty) years in the business and industry. Prior to Meera Industries Limited he has also worked with Garden Silk Mills Limited as Design Engineer, and with Premier Looms Manufacturers Private Limited as Product Head (TFO division). His functional responsibility in our Company involves handling the overall business affairs of the Company including planning business marketing strategies, capacity expansion, and overall development of the business of Meera Industries Limited. He has been on Board since the incorporation of the Company.

CIN: L74999GJ1980PLC003710

www.span.in



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: [contact@span.in](mailto:contact@span.in)

6	Disclosure of relationship between directors	Mr. Dharmesh Vinodbhai Desai is not related to any other Director of the Company
7	Name of other listed entities in which he also holds the directorship	Meera Industries Limited
8	Name of Committee(s) of listed entity(s) in which he is chairman/Member	Nil
9	Number of shares held in the Company	Nil
10	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE respectively	Mr. Dharmesh Vinodbhai Desai is not debarred from holding office of director by virtue of any SEBI Order or any such authority



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

## **Annexure- II**

**Relevant details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024**

Sr. No.	Particulars	Description
a.	Name	Mr. Nirav Dineshchandra Jogani (DIN: 00016354)
b.	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise;</del>	Resignation of Mr. Nirav Dineshchandra Jogani as an Independent Director of the Company.
c.	Date of <del>appointment/ re-appointment/ cessation &amp; term of appointment/re-appointment</del>	with effect from close of business hours on November 10, 2025
d.	Brief Profile (in case of appointment of a director)	Not Applicable
e.	Disclosure of relationships between directors (in case of appointment of director)	Not Applicable
f.	Letter of Resignation along with detailed reason for resignation	Enclosed
g.	Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	Nil
h.	The independent director shall, along with the detailed reasons, also provide a confirmation that there is no other material reason other than those provided.	Mr. Nirav Dineshchandra Jogani has confirmed that there is no other material reason for his resignation other than those mentioned in the resignation letter.

CIN: L74999GJ1980PLC003710

www.span.in



Date: November 10, 2025

To  
The Board of Directors  
Span Divergent Limited  
9th Floor, 902-904, Rajhans Bonista,  
Behind Ram Chowk Temple, Ghod Dod Road,  
Surat-395007

Dear Sir/ Madam

Sub: Resignation from the position of Independent Director, Span Divergent Limited

I, Nirav Dineshchandra Jogani, having DIN Number 00016354, wish to inform you that due to my other professional preoccupations and commitments, I am unable to devote adequate time to the affairs of the company and effectively contribute to the deliberations of the Board. Accordingly, I wish to resign from the position of Independent Director of the Company effective closure of business hours on November 10, 2025.

I further confirm that there is no other material reason other than as mentioned above for my stepping down from the position of Independent Director of the Company. I take this opportunity to express my sincere gratitude to all the Directors, the Promoters, and other stakeholders of the Company for the trust and confidence reposed in me during my tenure as an Independent Director of the Company and wish the Company every success in future.

Kindly accept my resignation and arrange for the necessary filings with the Registrar of Companies and the Stock Exchange, as per applicable regulations.

Thanking You,  
Yours faithfully



Nirav Dineshchandra Jogani  
DIN: 00016354



**Span Divergent Ltd.**  
(Formerly Span Diagnostics Ltd.)  
9th Floor, Rajhans Bonista,  
Behind Ram Chowk, Ghod Dod Road,  
Surat - 395 007, Gujarat, India  
Phone: +91 261 266 32 32  
E-Mail: contact@span.in

**Annexure- III**

**Relevant details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024**

Sr. No.	Particulars	Description
a.	Name	Dr. Pradipkumar Keshavlal Desai (DIN: 00026451)
b.	Reason for change viz. <del>appointment, re-appointment,</del> resignation, <del>removal,</del> death or otherwise;	Resignation of Dr. Pradipkumar Keshavlal Desai as Non-Executive and Non-Independent Director of the Company.
c.	Date of <del>appointment/ re-appointment/</del> cessation & <del>term of appointment/re-appointment</del>	with effect from close of business hours on November 10, 2025
d.	Brief Profile (in case of appointment of a director)	Not Applicable
e.	Disclosure of relationships between directors (in case of appointment of director)	Dr. Dr. Pradipkumar Keshavlal Desai is Father of Mr. Veeral Desai, Managing Director of the company
f.	Letter of Resignation along with detailed reason for resignation	Enclosed
g.	Names of other listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	Not Applicable
h.	Information as required under BSE Master Circular Number SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024	Not Applicable

CIN: L74999GJ1980PLC003710

www.span.in

Date: November 10, 2025

To  
The Board of Directors  
Span Divergent Limited  
9th Floor, 902-904, Rajhans Bonista,  
Behind Ram Chowk Temple, Ghod Dod Road,  
Surat-395007

Dear Sir/ Madam


Sub: Resignation from the position of Non-Executive and Non-Independent Director, Span Divergent Limited

I, Pradipkumar Keshavlal Desai, having DIN Number 00026451, wish to inform you that due to my advancing age, I hereby tender my resignation from position of Non-Executive and Non-Independent Director of company effective closure of business hours on November 10, 2025.

I further confirm that there is no other material reason other than as mentioned above for my stepping down from the position of Director of the Company. I take this opportunity to express my sincere gratitude to all the Directors and other stakeholders of the Company for the trust and confidence reposed in me during my tenure as Director of the Company and wish the Company every success in future.

Kindly accept my resignation and arrange for the necessary filings with the Registrar of Companies and the Stock Exchange, as per applicable regulations.

Thanking You,  
Yours faithfully



Pradipkumar Keshavlal Desai  
DIN: 00026451



**Span Divergent Ltd.**  
 (Formerly Span Diagnostics Ltd.)  
 9th Floor, Rajhans Bonista,  
 Behind Ram Chowk, Ghod Dod Road,  
 Surat - 395 007, Gujarat, India  
 Phone: +91 261 266 32 32  
 E-Mail: contact@span.in

#### **Annexure- IV**

Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

#### **Disinvestment of Stake of Span Divergent Limited held in Subsidiary LLP namely Span Diagnostics LLP**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Description</b>									
<b>1</b>	<b>Name of the Subsidiary LLP</b>	Span Diagnostics LLP, Subsidiary LLP (Non-Functional Subsidiary LLP)									
<b>2</b>	<b>The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year i.e. March 31, 2024</b>	Span Diagnostics LLP (a) Income and Net worth during Financial Year 2024 - 2025 <table border="1"> <thead> <tr> <th><b>Details</b></th><th><b>Amount (in INR Lakhs)</b></th><th><b>Percentage</b></th></tr> </thead> <tbody> <tr> <td><b>Total Income</b></td><td>0.00</td><td>0.00</td></tr> <tr> <td><b>Net Worth</b></td><td>0.15</td><td>0.00</td></tr> </tbody> </table>	<b>Details</b>	<b>Amount (in INR Lakhs)</b>	<b>Percentage</b>	<b>Total Income</b>	0.00	0.00	<b>Net Worth</b>	0.15	0.00
<b>Details</b>	<b>Amount (in INR Lakhs)</b>	<b>Percentage</b>									
<b>Total Income</b>	0.00	0.00									
<b>Net Worth</b>	0.15	0.00									
<b>3</b>	<b>Date on which the agreement for sale has been entered into</b>	November 10, 2025									
<b>4</b>	<b>The expected date of completion of sale/disposal</b>	November 10, 2025									
<b>5</b>	<b>Consideration received from such sale/disposal</b>	Not less than INR 99,000/-									
<b>6</b>	<b>Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof</b>	Mr. Viral P. Desai and Ms. Sujata V. Desai are the purchasers of Span's stake. Both Mr. Viral P. Desai and Ms. Sujata V. Desai belong to the promoter/promoter group of Span Divergent Limited.									
<b>7</b>	<b>Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"</b>	Transaction will be carried out at arm's length price.									
<b>8</b>	<b>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale</b>	Not Applicable									

CIN: L74999GJ1980PLC003710

www.span.in



Span Divergent Limited

(Formerly known as Span Diagnostics Limited)


Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710 Website: www.span.in

Statement of unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.

(Rs. in Lakhs except per share data)

Sr. No.	Particulars	Standalone					
		Three Months			Six Months		Year ended 31 March 2025
		Quarter ended 30 September 2025	Quarter ended 30 June 2025	Quarter ended 30 September 2024	Half Year ended 30 September 2025	Half Year ended 30 September 2024	
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	Other Operating Income	36.57	38.45	43.42	75.02	94.70	160.99
	Other income	19.27	26.48	26.41	45.75	48.68	115.20
	<b>Total income</b>	<b>55.84</b>	<b>64.93</b>	<b>69.83</b>	<b>120.77</b>	<b>143.38</b>	<b>276.19</b>
2	Expenses						
	Employee benefit expense	30.44	26.92	29.46	57.36	55.87	119.54
	Finance costs	-	-	-	-	-	-
	Depreciation and amortisation expense	6.44	6.28	6.29	12.72	12.60	25.16
	Other expenses	7.75	7.99	9.33	15.73	18.71	39.10
	<b>Total expenses</b>	<b>44.63</b>	<b>41.19</b>	<b>45.07</b>	<b>85.81</b>	<b>87.18</b>	<b>183.80</b>
3	Profit / (Loss) before exceptional items, Prior Period items and tax (1-2)	11.21	23.74	24.76	34.96	56.20	92.39
4	Exceptional items (Refer Note 5)	0.30	19.00		19.30	2.00	5.66
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>11.51</b>	<b>42.74</b>	<b>24.76</b>	<b>54.26</b>	<b>58.20</b>	<b>98.05</b>
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	(0.50)	1.07	0.59	0.57	10.94	14.09
7	<b>Profit/(Loss) for the period after tax (5-6)</b>	<b>12.01</b>	<b>41.67</b>	<b>24.17</b>	<b>53.69</b>	<b>47.26</b>	<b>83.96</b>
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net Income tax relating to items that will not be reclassified to Profit or Loss	(0.18)	(0.18)	(0.40)	(0.36)	(0.80)	(0.73)
		0.05	0.05	0.11	0.10	0.22	0.20
9	<b>Total comprehensive income for the year (7+8)</b>	<b>11.88</b>	<b>41.54</b>	<b>23.90</b>	<b>53.43</b>	<b>46.68</b>	<b>83.43</b>
10	<b>Paid-up equity share capital (Face value of Rs. 10/- each)</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>
11	<b>Other Equity</b>						<b>2,929.25</b>
	Earnings per equity share for profit from operation attributable to owners of the entity:						
12	Basic earnings per share	0.22	0.76	0.44	0.98	0.87	1.54
13	Diluted earnings per share	0.22	0.76	0.44	0.98	0.87	1.54



102



Note : -		
1. Statement of Assets and Liabilities as at September 30, 2025 and March 31, 2025 is given below:		
	Rs. In Lakh	
Particulars	Standalone	
	As at September 30, 2025	As at March 31, 2025
<b>Non-current assets</b>		
Property, plant and equipment	300.71	305.79
Capital Work In Progress	-	-
Right-of-use-assets	25.54	30.82
Investment properties	-	-
Other intangible assets	1.04	1.42
Intangible assets under development	-	-
Financial assets	-	-
i. Investments Non-current assets	3,116.26	2,931.83
ii. Others	25.99	35.99
iii. Loans Non-current assets	-	-
iv. Others Non-current assets	-	-
Deferred tax assets (Net)	8.64	8.45
Other non-current assets	-	-
<b>Total non-current assets</b>	<b>3,478.18</b>	<b>3,314.31</b>
<b>Current assets</b>		
Financial assets		
i. Investments Current assets	494.92	583.17
ii. Trade receivables Current assets	44.54	33.06
iii. Cash and cash equivalents	2.77	42.06
iv. Bank balances other than (iii) above	-	-
v. Loans Current assets	-	-
vi. Others Current assets	13.30	11.26
Current tax Assets (Net)	20.62	11.18
Other current assets	3.63	0.81
Assets classified as held for sale	-	-
<b>Total current assets</b>	<b>579.78</b>	<b>681.54</b>
<b>TOTAL</b>	<b>4,057.96</b>	<b>3,995.85</b>
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>Equity</b>		
Equity share capital/Partners capital	546.17	546.17
Other equity	2,982.68	2,929.25
<b>Total equity</b>	<b>3,528.85</b>	<b>3,475.42</b>
<b><u>LIABILITIES</u></b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
i. Borrowings Non-current liabilities	192.20	192.20
ii. Lease Liabilities	20.04	18.85
iii. Other financial liabilities Non-current liabilities	-	-
Provisions Non-current liabilities	66.74	64.50
Deferred tax liabilities (Net)	30.49	29.83
<b>Total non-current liabilities</b>	<b>309.47</b>	<b>305.38</b>
<b>Current liabilities</b>		
Financial liabilities		
i. Borrowings Current liabilities	-	-
ii. Lease liabilities	5.94	11.89
iii. Trade payables Current liabilities	-	-
A) total outstanding dues of micro enterprises and small enterprises; and	-	-
B) total outstanding dues of creditors other than micro enterprises and small enterprises	4.73	4.83
iv. Other financial liabilities Current liabilities	171.70	158.74
Other current liabilities	3.38	4.47
Provisions Current liabilities	33.89	35.12
Current tax liabilities	-	-
<b>Total current liabilities</b>	<b>219.64</b>	<b>215.05</b>
<b>TOTAL</b>	<b>4,057.96</b>	<b>3,995.85</b>



V D 2



- 2 Figures for the quarter ended September 30, 2025 are the balancing figures between the reviewed figures till September 30, 2025 and reviewed figures up-to the first quarter of the relevant financial year.
- 3 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2025.
- 4 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 10, 2025.
- 5 Other Operating Income comprises of Interest on fluctuating capital provided by the Company to its LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the period.
- 6 In case of subsidiary:
  - a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.12 Crores till March 31 2025 and gain of Rs. 0.19 crore in the current year, up to September 30, 2025. The Board has approved the plan to revive the operations of LLP, in light of new opportunities emerging and accordingly the assets of LLP has been reclassified as part of PPE.
  - (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
  - (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs. 6.65 Crores till September 30, 2025. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.55 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 7 Previous periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited



Viral Desai  
Managing Director  
DIN : 00029219

Place : Surat

Date : November 10, 2025





## 8. Statement of Cash Flows for the Year Ended September 30, 2025.

Particular	Half Year ended 30 September 2025	Year ended 31 March 2025
Profit before income tax	54.26	98.04
Adjustments for	-	-
Depreciation and amortisation expense	12.72	25.16
Intangible Assets Written Off	-	-
Un realised Loss/(Gain) on Investments	(12.04)	(41.18)
Dividend and interest income classified as investing cash flows	-	-
Rental Income	(20.68)	(48.54)
Interest Income	(1.22)	(3.59)
Gain on Sale of Investments	(9.40)	-
Gain on Sale of Assets	(0.10)	(1.45)
Finance Cost	-	-
Financial Guarantee Fees Income	(2.31)	(4.39)
Balances Written Back	-	-
Impairment Provision for LLP Subsidiaries	(19.30)	(5.66)
Rental Expense	-	-
Change in operating assets and liabilities:	-	-
(Increase)/Decrease in trade receivables-Current	(11.48)	(14.01)
Increase in trade payables- current	(0.10)	3.16
(Increase) in other financial assets-current	(2.04)	-0.61
(Increase)/decrease in other non-current assets	-	-
(Increase)/decrease in other current assets	(2.82)	0.06
Increase/(decrease) in provisions-Non Current	1.87	37.17
Increase/(decrease) in provisions-Current	(1.23)	-
Increase/(decrease) in other financial liabilities-current	12.97	22.88
Increase in other current liabilities	(1.09)	(0.92)
Cash generated from operations	(1.99)	66.11
Income taxes paid	9.45	(33.80)
Net cash inflow from operating activities	(11.44)	99.91
Cash flows from investing activities	-	-
(Purchase)/Redemption of investments in Subsidiary	(165.13)	(73.08)
Proceeds from sale of investments	109.69	(73.48)
Investment in Fixed Deposits for more than one year	10.00	14.09
(Purchase)/Sale of property, plant and equipment	(1.87)	(30.47)
Dividends received	-	-
Rental Income	20.68	48.54
Interest received	3.53	4.00
Net cash outflow from investing activities	(23.10)	(110.40)
Cash flows from financing activities	-	-
Proceeds/(Repayment to) from borrowings	-	(5.50)
Changes in Lease Liabilities	(4.76)	20.28
Payment towards unclaimed dividend	-	-
Interest paid	-	-
Net cash inflow (outflow) from financing activities	(4.76)	14.78
Net increase (decrease) in cash and cash equivalents	(39.30)	4.28
Cash and cash equivalents at the beginning of the financial year	42.06	37.78
Cash and cash equivalents at end of the year	2.76	42.06
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
Particulars	Half Year ended 30 September 2025	Year ended 31 March 2025
Balances with banks		
- in current accounts	2.73	42.03
Cash on hand	0.03	0.03
Balances per statement of cash flows	2.76	42.06





Span Divergent Limited

(Formerly known as Span Diagnostics Limited)

Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007

CIN:L74999GJ1980PLC003710, Website: www.span.in

Statement of Consolidated unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.

Rs. In Lakh

Sr. No.	Particulars	Consolidated					
		Three Months			Six Months		Year ended 31 March 2025
		Quarter ended 30 September 2025	Quarter ended 30 June 2025	Quarter ended 30 September 2024	Half Year ended 30 September 2025	Half Year ended 30 September 2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Sale of Traded Products/Services	756.63	96.23	269.33	852.86	621.58	855.01
	Other Operating Income	7.80	10.80	11.25	18.60	30.00	41.00
	Other income	21.83	72.18	24.73	94.01	42.25	118.84
	<b>Total income</b>	<b>786.26</b>	<b>179.22</b>	<b>305.31</b>	<b>965.47</b>	<b>693.83</b>	<b>1,014.85</b>
2	Expenses						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of stock-in-trade	645.46	423.99	16.62	1,069.44	109.20	279.65
	Changes in inventories of work-in-progress, stock-in-trade and finished goods	(2.56)	(354.23)	9.66	(356.79)	55.85	16.29
	Employee benefit expense	53.84	51.16	62.07	105.00	114.58	230.51
	Finance costs	11.88	11.92	15.29	26.45	31.51	60.39
	Depreciation and amortisation expense	26.69	27.23	28.43	51.27	56.61	108.80
	Other expenses	67.74	52.60	167.55	120.34	320.20	433.21
	<b>Total expenses</b>	<b>803.05</b>	<b>212.67</b>	<b>299.62</b>	<b>1,015.71</b>	<b>687.94</b>	<b>1,128.85</b>
3	<b>Profit / (Loss) before tax and Exceptional items (1-2)</b>	<b>(16.79)</b>	<b>(33.45)</b>	<b>5.69</b>	<b>(50.24)</b>	<b>5.89</b>	<b>(114.00)</b>
4	Exceptional items	0.30	19.00	-	19.30	2.00	5.66
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>(16.49)</b>	<b>(14.45)</b>	<b>5.69</b>	<b>(30.94)</b>	<b>7.89</b>	<b>(108.34)</b>
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	2.28	2.55	1.04	4.84	11.76	19.03
7	<b>Profit/(Loss) for the period after tax (5-6)</b>	<b>(18.77)</b>	<b>(17.01)</b>	<b>4.65</b>	<b>(35.78)</b>	<b>(3.87)</b>	<b>(127.37)</b>
	Profit for the year attributable to:						
	(a) Owners of the Company	(13.43)	(9.83)	12.64	(23.26)	12.10	(91.73)
	(b) Non Controlling Interest	(5.34)	(7.18)	(7.99)	(12.52)	(15.97)	(35.64)
		(18.77)	(17.01)	4.65	(35.78)	(3.87)	(127.37)
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	(0.005)	(0.005)	0.39	(0.01)	0.79	(0.02)
	Income tax relating to items that will not be reclassified to Profit or Loss	0.005	0.005	(0.15)	0.01	(0.30)	0.02
	<b>Other comprehensive income</b>	<b>(0.00)</b>	<b>(0.00)</b>	<b>0.25</b>	<b>0.02</b>	<b>0.49</b>	<b>(0.00)</b>
	Other comprehensive income attributable to:						
	(a) Owners of the Company	0.05	0.04	0.30	0.09	0.61	0.22
	(b) Non Controlling Interest	(0.05)	(0.05)	(0.06)	(0.11)	(0.12)	(0.22)
		(0.00)	(0.01)	0.25	(0.01)	0.49	(0.00)
9	<b>Total comprehensive income for the year (7+8)</b>	<b>(18.77)</b>	<b>(17.02)</b>	<b>4.89</b>	<b>(35.78)</b>	<b>(3.38)</b>	<b>(127.37)</b>
	Total comprehensive income attributable to:						
	(a) Owners of the Company	(13.48)	(9.89)	12.83	(23.37)	12.48	(91.95)
	(b) Non Controlling Interest	(5.29)	(7.12)	(7.93)	(12.41)	(15.86)	(35.42)
		(18.77)	(17.02)	4.89	(35.78)	(3.38)	(127.37)
10	<b>Paid-up equity share capital (Face value of Rs. 10/- each)</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>	<b>546.17</b>
11	<b>Other Equity</b>						<b>(826.86)</b>
	Earnings per equity share for profit from operation attributable to owners of the entity:						
12	Basic earnings per share *	(0.34)	(0.31)	0.09	(0.66)	(0.07)	(2.33)
13	Diluted earnings per share *	(0.34)	(0.31)	0.09	(0.66)	(0.07)	(2.33)

\* For the period only and not annualised



**Note :-**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 10, 2025.
- 2 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2025.
- 3 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016.
- 4 In case of subsidiary:
  - a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.12 Crores till March 31 2025 and gain of Rs. 0.19 crore in the current year, up to September 30, 2025. The Board has approved the plan to revive the operations of LLP, in light of new opportunities emerging and accordingly the assets of LLP has been reclassified as part of PPE.
  - (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
  - (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulated losses of Rs. 6.65 Crores till September 30, 2025. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.55 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon.
- 5 In pursuance to Section 115BAA of the Income Tax Act, 1961 announced by Government of India through Taxation Laws (Amendment) Ordinance, 2019, the Company has an irrevocable option of shifting to a lower tax rate along with consequent reduction in certain tax incentive including additional depreciation and accumulated depreciation in any subsequent year(s). The Company is evaluating this option and continues to recognise the taxes on income for the quarter and period ended September 30, 2025 as per the earlier provisions.
- 6 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited



Viral Desai  
Managing Director

Place : Surat

Date : November 10, 2025

DIN: 00029219



## SPAN DIVERGENT LIMITED

(Formerly known as Span Diagnostics Limited)

## 7. Consolidated Balance Sheet at the Half Year ended September 30, 2025.

Rs. In Lakh

Particulars	As at September 30, 2025	As at March 31, 2025
	(unaudited)	(audited)
<b>ASSETS</b>		
Non-current assets	-	
Property, plant and equipment	954.37	941.38
Right-of-use-assets	31.09	21.43
Capital work-in-progress	-	-
Investment properties	-	-
Goodwill	-	-
Intangible assets	1.05	1.43
Intangible assets under development	-	-
Biological assets other than bearer plants	-	-
Financial assets	-	-
i. Investments	-	-
ii. Trade Receivables	-	-
ii. Loans	-	-
i. Others	25.99	36.00
Deferred tax assets (Net)	34.95	36.58
Other non-current assets	-	-
Assets classified as held for sale	-	45.15
<b>Total non-current assets</b>	<b>1,047.45</b>	<b>1,081.97</b>
Current assets		
Inventories	457.34	99.94
Financial assets	-	-
i. Investments	543.08	629.99
ii. Trade receivables	151.78	138.66
iii. Cash and cash equivalents	52.30	58.53
iv. Bank balances other than (iii) above	47.87	45.05
v. Loans	-	-
v. Others	18.64	21.59
vi. Other Financial Assets	20.62	11.18
Current tax Assets (Net)	10.03	9.96
Other current assets	407.85	223.35
Assets classified as held for sale	-	-
<b>Total current assets</b>	<b>1,709.51</b>	<b>1,238.25</b>
<b>Total assets</b>	<b>2,756.96</b>	<b>2,320.22</b>
<b>EQUITY AND LIABILITIES</b>		
Equity		
Equity share capital	546.17	546.17
Other equity	(850.23)	(826.85)
Ind AS 116 Entry	-	-
Non Controlling Interest	(615.86)	(603.45)
	<b>(919.92)</b>	<b>(884.13)</b>
<b>LIABILITIES</b>		
Non-current liabilities		
Financial Liabilities		
i. Borrowings	192.20	240.22
ii. Lease Liability	20.04	18.85
iii. Trade Payables	-	-
iii. Other financial liabilities (to be specified)	-	-
Provisions	86.65	82.39
Deferred tax liabilities (Net)	49.81	46.60
Other non-current liabilities	25.35	26.85
<b>Total non-current liabilities</b>	<b>374.05</b>	<b>414.91</b>
Current liabilities		
Financial liabilities		
i. Borrowings	510.24	564.38
ii. Lease liabilities	11.58	11.89
iii. Trade payables	-	-
A) total outstanding dues of micro enterprises and small enterprises; and	72.94	0.49
B) total outstanding dues of creditors other than micro enterprises and small enterprises	630.34	345.17
iv. Other financial liabilities	189.18	173.37
Other current liabilities	98.32	25.70
Provisions	1,790.24	1,668.45
Current tax liabilities	-	-
<b>Total current liabilities</b>	<b>3,302.83</b>	<b>2,789.45</b>
<b>Total liabilities</b>	<b>3,676.88</b>	<b>3,204.36</b>
<b>Total equity and liabilities</b>	<b>2,756.96</b>	<b>2,320.22</b>



## 8. Consolidated Cash Flow Statement as at September 30, 2025

Particulars	As at 30 September 2025	As at 31 March 2025
Profit before income tax	(30.94)	(108.34)
Adjustments for	-	-
Depreciation and amortisation expense	51.27	108.80
Intangible Asset Written off	-	-
Capital Assets Write off	-	-
Dividend and interest income classified as investing cash flows	-	-
Rental Income	(20.68)	(48.54)
Interest Income	(3.06)	(3.87)
Gain on Sale of Investments	(9.40)	(1.50)
Unrealised Gain Loss on Biological Assets/Investments	(13.39)	(42.99)
Finance Cost	26.45	60.39
Balances Written Back	-	10.68
(Gain)/Loss on Sale property, plant and equipment	(0.10)	0.05
Impairment of Investments	(19.30)	(5.66)
Change in operating assets and liabilities:	-	-
(Increase)/Decrease in trade receivables- current	(13.13)	5.55
(Increase)/Decrease in Inventory- current	(357.40)	18.26
(Increase)/Decrease in Biological Assets	-	-
Increase in trade payables-current	357.61	70.80
(Increase) in other financial assets-non-current	10.00	24.60
(Increase) in other financial assets-current	2.96	-
(Increase)/decrease in other non-current assets	-	-
(Increase)/decrease in other current assets	(184.50)	32.79
Increase/(decrease) in provisions- non current	4.26	6.70
Increase/(decrease) in provisions- current	285.08	-
Increase/(decrease) in other financial liabilities-current	15.81	20.61
Increase in other current liabilities-non current	0.31	-
Increase in other current liabilities-current	(72.31)	(28.03)
Cash generated from operations	29.54	120.29
Income taxes paid	(9.51)	65.52
Net cash inflow from operating activities	20.03	185.81
Cash flows from investing activities	-	-
Proceeds / (Purchase) from sale of investments	106.88	(161.99)
Purchase of property, plant and equipment	-	-
Proceeds from sale/(Purchase) of property, plant and equipment	(28.27)	4.77
Rental Income	20.68	48.54
Interest received	3.06	3.87
Net cash outflow from investing activities	102.35	(104.81)
Cash flows from financing activities	-	-
Proceeds/Repayment from borrowings	(102.15)	(54.59)
Payment towards unclaimed dividend	-	-
Interest paid	(26.45)	(60.39)
Net cash inflow (outflow) from financing activities	(128.60)	(114.97)
Net increase (decrease) in cash and cash equivalents	(6.22)	(33.98)
Cash and cash equivalents at the beginning of the financial year	58.52	92.51
Cash and cash equivalents at end of the year	52.30	58.53
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
Particulars	As at 30 September 2025	As at 31 March 2025
Balances with banks and Cash on hand	52.30	58.53
Balances per statement of cash flows	52.30	58.53




## 9. Consolidated Segment Revenue, Results Assets and Liability as at September 30, 2025.

(Rs. In Lakhs)

Sr. No.	Particulars	Three Months			Six Months		Year ended 31 March 2025
		Quarter ended 30 September 2025	Quarter ended 30 June 2025	Quarter ended 30 September 2024	Half Year ended 30 September 2025	Half Year ended 30 September 2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Segment Revenue						
	- Cashew processing	657.70	15.27	238.75	672.98	515.51	585.62
	- Tissu Culture	-	-	-	-	-	-
	- Trading	104.26	111.34	55.68	215.60	110.51	294.59
	Gross Revenue from Operations from Segments	761.96	126.61	294.43	888.58	626.02	880.22
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Revenue from Operations from Segments	761.96	126.61	294.43	888.58	626.02	880.22
2	Segment Results						
	Profit / (Loss) before Interest and tax						
	- Cashew processing	(23.27)	(65.91)	9.16	(89.18)	(14.06)	(160.55)
	- Tissu Culture	-	-	-	-	-	-
	- Trading	(5.75)	(11.25)	7.83	(17.01)	(35.52)	(47.28)
	- Unallocable Income over expenses like (Including HO)	12.53	62.70	(11.30)	75.25	38.31	99.49
	Total Profit / (Loss) before Tax	(16.49)	(14.46)	5.69	(30.94)	(11.27)	(108.34)
3	Segment Assets						
	- Cashew processing	1,321.03	1,215.56	1,034.00	1,321.03	1,034.00	880.18
	- Tissu Culture	70.57	70.59	94.83	70.57	94.83	90.44
	- Trading	455.65	376.41	188.30	455.65	188.30	328.05
	- Unallocable	909.71	4,086.19	1,015.50	909.71	1,015.50	1,021.56
	Total Assets	2,756.96	5,748.75	2,332.64	2,756.96	2,332.64	2,320.22
4	Segment Liability						
	- Cashew processing	642.61	621.42	349.79	642.61	349.79	294.90
	- Tissu Culture	9.69	9.75	29.66	9.69	29.66	29.56
	- Trading	959.17	873.99	663.07	959.17	663.07	814.39
	- Unallocable	2,065.41	569.07	2,023.08	2,065.41	2,023.08	2,065.50
	Total Liability	3,676.88	2,074.23	3,065.60	3,676.88	3,065.60	3,204.36

For, Span Divergent Limited



Viral Desai  
Managing Director  
DIN: 00029219

Place : Surat

Date : November 10, 2025





**Independent Auditor's Review Report on the Quarterly and Year to Date  
Unaudited Standalone Financial Results of the Company Pursuant to the  
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015, as amended**

Review Report to

To the Board of Directors of

**Span Divergent Ltd.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Span Divergent Limited** ("the Company") for the quarter ended **September 30, 2025** and year to date from April 01, 2025 to September 30, 2025 (the "statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Y. B. Desai and Associates  
Chartered Accountants  
Firm Registration No. 102368W



Mayank Y. Desai  
Partner  
Membership No. :- 108310

UDIN: 25106310BMISF8820

Date :- 10<sup>th</sup> November, 2025

Place :- Surat





1 / 573, 1st FLOOR, GAJANAND COMPLEX, POR MOHALLOW, NEAR ANAND HOSPITAL, NANPURA, SURAT - 395 001.

**Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

Review Report to  
The Board of Directors  
Span Divergent Ltd.

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Span Divergent Limited** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended September 30, 2025 and year to date from **April 01, 2025 to September 30, 2025** (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including (the "Listing Regulation").
2. This Statement, which is the responsibility of the Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. The Statement includes the results of the following entities:

**Parent Company:**

- i. Span Divergent Limited





**Subsidiary:**


- Dryfruit Factory LLP
- Aranya Agri Biotech LLP
- Span Diagnostics LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of subsidiary have been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of this entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary, is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of above matter is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Y. B. Desai and Associates  
Chartered Accountants  
Firm Registration No. 102368W

  
Mayank Y. Desai  
Partner

Membership No. :- 108310

UDIN: 25108310 BM1559 7507



Date :- 10<sup>th</sup> November, 2025

Place :- Surat